CN Patent

CN121175071A — 使用il-2缀合物的新型癌症治疗方法

Assigned to Asendis Pharmaceutical Oncology Co ltd · Expires 2025-12-19 · 0y expired

What this patent protects

本发明涉及IL‑2缀合物或其药学上可接受的盐，其用于治疗癌症，其中，所述IL‑2缀合物以80 µg IL‑2/kg至160 µg IL‑2/kg的剂量范围施用，和其中所述IL‑2缀合物具有式(I)；本发明还涉及相关方面。

USPTO Abstract

本发明涉及IL‑2缀合物或其药学上可接受的盐，其用于治疗癌症，其中，所述IL‑2缀合物以80 µg IL‑2/kg至160 µg IL‑2/kg的剂量范围施用，和其中所述IL‑2缀合物具有式(I)；本发明还涉及相关方面。

Drugs covered by this patent

Yorvipath (PALOPEGTERIPARATIDE) · Ascendis Pharma Bone

Patent Metadata

Patent number: CN121175071A
Jurisdiction: CN
Classification: —
Expires: 2025-12-19
Drug substance claim: No
Drug product claim: No
Assignee: Asendis Pharmaceutical Oncology Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.